PMID- 31189151
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200930
IS  - 1523-7834 (Print)
IS  - 1523-7834 (Linking)
VI  - 45
IP  - 2
DP  - 2019
TI  - Clinical Implications of Simultaneous Occurrence of Variant Philadelphia 
      Translocations in Chronic Myeloid Leukemia.
PG  - 61-65
AB  - Up to 90% of cases of chronic myeloid leukemia (CML) are myeloproliferative 
      disorders characterized by a Philadelphia (Ph) chromosome with a classical 
      t(9;22)(q34;q11). Of all CML patients, 5-10% show variant Philadelphia 
      translocations (vPh) and are an area of research interest for their significance 
      in predicting response to various therapies, including tyrosine kinase 
      inhibitors. They are also being studied for prognosticating multi-year survival 
      outcomes in varied patient populations, with conflicting results. We included 238 
      patients for conventional cytogenetic and fluorescence in situ hybridization 
      study from January 2018 to October 2018. Patients with vPh in CML-Chronic Phase 
      (CML-CP) were analyzed with respect to their demographic parameters, response to 
      imatinib therapy, and survival. Out of 238 patients diagnosed with CML-CP, 8 
      patients (3.3%) showed vPh. The most common chromosomes involved in these 
      translocations were 1, 2, 3, 4, 7, 11 and 12. In almost all the cases with 
      variant Ph chromosome, the BCR-ABL rearrangement was detected by molecular 
      methods or by fluorescence in situ hybridization (FISH). All patients were 
      treated with imatinib as a first-line therapy. Rates of complete hematological 
      response, complete cytogenetic response, and major molecular response were 
      similar in all patients with classical Ph and variant Ph chromosome. Our data 
      suggest that prognosis of CML patients with vPh in CML has no significant effect 
      in predicting response to imatinib or in predicting survival.
CI  - Copyright(c) by the Association of Genetic Technologists.
FAU - Trivedi, Pina
AU  - Trivedi P
AD  - Cytogenetic Lab, Department of Cancer Biology, Gujarat Cancer and Research 
      Institute, Asarwa, Ahmedabad-380016, India.
FAU - Varma, Priya
AU  - Varma P
AD  - Cytogenetic Lab, Department of Cancer Biology, Gujarat Cancer and Research 
      Institute, Asarwa, Ahmedabad-380016, India.
FAU - Patel, Dharmesh
AU  - Patel D
AD  - Cytogenetic Lab, Department of Cancer Biology, Gujarat Cancer and Research 
      Institute, Asarwa, Ahmedabad-380016, India.
FAU - Ladani, Dhara
AU  - Ladani D
AD  - Cytogenetic Lab, Department of Cancer Biology, Gujarat Cancer and Research 
      Institute, Asarwa, Ahmedabad-380016, India.
FAU - Patel, Darshita
AU  - Patel D
AD  - Cytogenetic Lab, Department of Cancer Biology, Gujarat Cancer and Research 
      Institute, Asarwa, Ahmedabad-380016, India.
FAU - Kazi, Mahnaz
AU  - Kazi M
AD  - Cytogenetic Lab, Department of Cancer Biology, Gujarat Cancer and Research 
      Institute, Asarwa, Ahmedabad-380016, India.
FAU - Patel, Nehal
AU  - Patel N
AD  - Cytogenetic Lab, Department of Cancer Biology, Gujarat Cancer and Research 
      Institute, Asarwa, Ahmedabad-380016, India.
FAU - Patel, Prabhudas
AU  - Patel P
AD  - Cytogenetic Lab, Department of Cancer Biology, Gujarat Cancer and Research 
      Institute, Asarwa, Ahmedabad-380016, India.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Assoc Genet Technol
JT  - Journal of the Association of Genetic Technologists
JID - 9807282
EDAT- 2019/06/13 06:00
MHDA- 2019/06/13 06:01
CRDT- 2019/06/13 06:00
PHST- 2019/06/02 00:00 [received]
PHST- 2019/09/10 00:00 [accepted]
PHST- 2019/06/13 06:00 [entrez]
PHST- 2019/06/13 06:00 [pubmed]
PHST- 2019/06/13 06:01 [medline]
PST - ppublish
SO  - J Assoc Genet Technol. 2019;45(2):61-65.